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Generation of orthotopic xenograft mouse models of leukemia is important to under-
stand the mechanisms of leukemogenesis, cancer progression, its cross talk with the 
bone marrow microenvironment, and for preclinical evaluation of drugs. In these models, 
following intravenous injection, leukemic cells home to the bone marrow and proliferate 
there before infiltrating other organs, such as spleen, liver, and the central nervous sys-
tem. Moreover, such models have been shown to accurately recapitulate the human 
disease and correlate with patient response to therapy and prognosis. Thus, various 
immune-deficient mice strains have been used with or without recipient preconditioning 
to increase engraftment efficiency. Mice homozygous for the severe combined immune 
deficiency (SCID) mutation and with non-obese diabetic background (NOD/SCID) have 
been used in the majority of leukemia xenograft studies. Later, NOD/SCID mice defi-
cient for interleukin 2 receptor gamma chain (IL2Rγ) gene called NSG mice became the 
model of choice for leukemia xenografts. However, engraftment of leukemia cells with-
out irradiation preconditioning still remained a challenge. In this study, we used NSG 
mice with null alleles for major histocompatibility complex class I beta2-microglobulin 
(β2m) called NSG-B2m. This is a first report describing the 100% engraftment efficiency 
of pediatric leukemia cell lines and primary samples in NSG-B2m mice in the absence 
of host preconditioning by sublethal irradiation. We also show direct comparison of the 
engraftment efficiency and growth rate of pediatric acute leukemia cells in NSG-B2m 
and NOD/SCID mice, which showed 80–90% engraftment efficiency. Secondary and 
tertiary xenografts in NSG-B2m mice generated by injection of cells isolated from the 
spleens of leukemia-bearing mice also behaved similar to the primary patient sample. 
We have successfully engrafted 25 acute lymphoblastic leukemia (ALL) and 5 acute 
myeloid leukemia (AML) patient samples with distinct cytogenetic characteristics in 
NSG-B2m mice, with the purpose of generating pediatric ALL and AML xenografts for 
preclinical evaluation of drugs. Thus, our data support the use of NSG-B2m mouse 
model for leukemia engraftment and in vivo preclinical drug efficacy studies.
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inTrODUcTiOn
Acute leukemia is the most common malignancy in children. 
Leukemia is characterized by the proliferation of immature 
blasts in the bone marrow that gradually infiltrate the spleen, 
liver, lymph nodes, and sometimes the central nervous system 
(CNS). With ~3000 pediatric cases diagnosed in the US annu-
ally (1), acute lymphoblastic leukemia (ALL) originating from 
neoplastic lymphoid progenitors is more prevalent than acute 
myeloid leukemia (AML). ALL is classified as B-cell ALL (B-ALL) 
or T-cell ALL (T-ALL) depending on the specific immunophe-
notypic characteristic of the progenitor clone, B-cell precursor or 
T-cell lineage, respectively. AML arises from genetic changes in 
myeloid progenitor cells leading to their aberrant expansion. The 
incidence rate of AML is ~7 per 1 million children per year (2).
Primary leukemia cells cannot be cultured in  vitro for long 
periods, but leukemia xenografts have proven extremely useful, 
not only for passaging primary samples but also for the modeling 
of the human disease in mice (3). In these models, human cell 
lines or leukemia cells isolated from patients are intravenously 
injected into immunodeficient mice to generate systemic disease. 
Leukemia cells engraft and proliferate in the bone marrow 
followed by infiltration into the spleen, liver, and other organs 
including CNS (4). The progression of the disease in mice can be 
tracked in real time by sampling murine peripheral blood (5, 6). 
These models accurately recapitulate the disease characteristics, 
such as blast morphology, immunophenotype, and sites of organ 
infiltration (5). Hind limb paralysis is a common symptom owing 
to the infiltration of leukemic cells into the CNS in some mice 
(7), consistent with the involvement of the CNS in a small patient 
population (8, 9).
The suitability of xenograft models for preclinical testing 
of novel drugs or novel combinations of existing drugs was 
established by studies showing the correlation of xenograft drug 
responses with patient clinical outcome (6). Although the lack 
of a native immune system in these immune-deficient mouse 
hosts prevents the study of interaction between the tumor and 
the immune system, these mouse models can be effectively used 
for deciphering the role of the bone marrow microenvironment 
on leukemia cell growth and chemoresistance (10, 11). That 
leukemic cells alter the bone marrow niche to their liking and 
thereby disrupt normal hematopoiesis was demonstrated using 
these mouse models (12). The identification of a therapy-induced 
niche that supports the survival of cancer-propagating cells that 
ultimately lead to disease relapse was possible by using xenotrans-
plantation of ALL cells in immune-deficient mice (13). Thus, the 
benefits of using leukemia xenograft models for understanding 
leukemia disease biology have been established (14).
Non-obese diabetic/severe combined immunodeficient (NOD/
SCID) mice pre-conditioned with sublethal irradiation are the 
most commonly used recipients for the engraftment of patient-
derived leukemic cells for preclinical testing (15). However, the 
engraftment efficiency is reported to be lower in the absence of 
irradiation pretreatment. This is believed to be due to the pres-
ence of innate immunity and remnants of the immune system 
in NOD/SCID mice. Some young adult mice can generate a 
few clones of B-cells and T-cells due to leakiness of the SCID 
mutation, although it is minimal in mice with the NOD back-
ground (16). To overcome this hurdle, other groups used NOD/
SCID mice null for the major histocompatibility complex (MHC) 
class I molecule beta2-microglobulin gene (NS-β2m) (17,  18) 
or NOD/SCID mice with interleukin 2 receptor gamma gene 
(IL2Rγ) deletion (NSG) (19–21). We utilized NOD/SCID mice 
with deletions in both these genes (NSG-B2m) for establishment 
of xenograft mouse models. Although NSG-B2m mice have been 
used earlier for graft-versus-host disease studies (22, 23), ours 
was the first group to use this mouse model for generation of 
leukemia xenografts. Our data show that NSG-B2m mice sup-
port engraftment of primary human ALL and AML samples with 
diverse cytogenetic characteristics (Table  1) in the absence of 
irradiation preconditioning and at 100% engraftment efficiency.
MaTerials anD MeThODs
cell lines and Patient samples
AML-193 (CRL-9589), HL-60 (CCL-240), MV4;11 (CRL-9591), 
REH (CRL-8286), RS4;11 (CRL-1873) cells were obtained from 
American Type Culture Collection (ATCC), Manassas, VA, USA. 
Nalm6 cells were purchased from DSMZ-German Collection of 
Microorganisms and Cell Cultures, Braunschweig, Germany. 
RS4;11, REH, and Nalm6 cells were cultured in RPMI culture 
medium supplemented with 10% fetal bovine serum (FBS), 
2 mM/L l-glutamine, 25 U/ml penicillin, and 25 μg/ml strepto-
mycin. MV4;11 and HL-60 cells were cultured in IMDM culture 
medium with supplements listed above, except that 20% serum 
was used for HL-60 cells. AML-193 cells were cultured in IMDM 
with 5% FBS, 0.5 ng/ml insulin, 5 ng/ml transferrin receptor, and 
5 ng/ml GM-CSF.
Primary leukemia samples collected under a Nemours 
Delaware Institutional Review Board (IRB) protocol approved by 
the Nemours Office of Human Subjects Protection were provided 
by the Nemours BioBank. Bone marrow aspirates or peripheral 
blood of patients treated at Nemours/Alfred I. duPont Hospital 
for Children were subjected to Ficoll (Ficoll Paque Plus, GE 
Healthcare Bio-Sciences, Pittsburgh, PA, USA) density gradient 
centrifugation. Cells isolated from the interphase had at least 90% 
of leukemic blasts as determined by flow cytometry.
antibodies
FITC-conjugated human CD45, CD10, CD19, CD3, CD33 and 
APC-conjugated mouse CD45 and human CD45 antibodies were 
obtained from Affymetrix eBioscience (San Diego, CA, USA).
Flow cytometry
Mouse peripheral blood was collected periodically by subman-
dibular bleeding. Blood was stained with FITC-conjugated 
human CD45 and APC-conjugated mouse CD45 antibodies. The 
red blood cells (RBC) were lysed by using a multispecies RBC lysis 
buffer (Affymetrix eBioscience) containing ammonium chloride. 
Following RBC lysis, the number of cells stained specifically for 
either antibody (CD45+ cells) within a cell population gated for 
lymphocytes or myeloid cells (based on their forward and side 
scatter parameters) was determined by flow cytometry using a 
TaBle 1 | cytogenetic characteristics of patient samples engrafted.
iD no. ethnicity age gender Diagnosis Fish Karyotype
NTPL-20 African American 6 M B-ALL BCR/ABL1 translocation, 
p16 gene deletion
46XY, der(9)del(9)(p21.3)inv(9)(q32p21.2)ins(9;22)
(q34;q11.2),der(22)t(9;22)(q34;q11.2)[13]/46XY[7]
NTPL-24 Caucasian 4 M T-ALL Negative 46XY, del(6)(q21),del(9)(p22)[cp7]/46XY[13]
NTPL-26 Caucasian 4 F B-ALL TEL/AML1 (ETV6/RUNX1) 
fusion, MLL gene deletion
47XX,+21c[cp12]/47,idem,del(9)(p21),del(11)
(q23),−13,+mar[cp8]
NTPL 59 Caucasian 1 F T-ALL Negative 46XX
NTPL-60 African American 4 M AML AML1 and ETO amplification 46XY, der (14;21) (q10;q10) ?c, +21c [cp12]/48, idem, +8, 
+der (14;21) (q10; q10) [cp8]
NTPL-83 Caucasian 4 F B-ALL TEL/AML1 (ETV6/RUNX1) 
fusion
47XX, +21 [6]/46XX [14]
NTPL-84 Asian 8 F B-ALL Hyperdiploidy, p16 gene 
deletion
52XX,+X,+4,dic(4;6)(p12q11.2),+6,+14,+17,+21, 
+21[cp7]/46XX[13]
NTPL-87 Caucasian 14 M B-ALL Normal 46XY
NTPL-90 Not known 3 F B-ALL ETV6/RUNX1 fusion 46XX
NTPL-92 African American 
and Caucasian
5 F B-ALL E2A/PBX1 gene fusion 46XX, der(19)t(1;19)(q23;p13)[2]/46XX[18]
NTPL-103 Caucasian 4 F B-ALL Trisomy 21 47XX, +21 
NTPL-104 Caucasian 11 F AML C/EBPalpha mutation 46XX
NTPL-109 Hispanic 3 M B-ALL E2A gene deletion 46XY
NTPL-119 Hispanic 3 F B-ALL RUNX1 amplification 46XX, ?ins(7;15) (?p15;?q12q26), −9, +mar[cp3]/46, XX [17]
NTPL-127 Caucasian 7 M B-ALL RUNX1 amplification 46XY
NTPL 137 Caucasian 7 F B-ALL Hyperdiploidy, trisomy 4, 10, 
tetrasomy 21
Pending
NTPL-138 Hispanic 4 M B-ALL Hyperdiploidy, p16 gene 
deletion
58XY, +X, +4, +6, +7, +10, +14, del(16)(q22), +17, +18, 
+21, +21 +2mar[cp6]/46, XY [14]
NTPL-150 Hispanic 7 M B-ALL Hyperdiploidy, p16 gene 
deletion, RUNX1 gain
51–52XY, +add(X)(22.3), i(8)(q10), dic(9;20)(p11.2;q11.2), 
del(9)(p21), +14, +18, +21, +21, +21, +21 [cp5/46, XY[15]]
NTPL-155 Hispanic 16 M B-ALL p16 gene deletion 46XY
NTPL-164 African American 4 M B-ALL p16 gene deletion 46XY, del(9)(p21)[cp2]/46, XY [18]
NTPL-168 African American 5 M B-ALL Negative 46XY 
NTPL-216 Not known 2 F B-ALL ETV6/RUNX1 fusion, p16 
gene deletion
46XX 
NTPL 301 Caucasian 13 F AML Monosomy 5, monosomy 7, 
TEL deletion
42 ~ 43, X, t(2;16)(q21;p13.1),add(4)(q21),der(5)t(5;12)
(q13;q11.2),−7,add(12)(p11.2),add(15)(q22,−17,−19,add(20)
(p13),+1 ~ 2mar[cp8/42,sl,−13[cp5]]/42,sdl1,+del(13)
(q12q14),−add(20)[2]/42,sdl2,−der(5),+add(7)(q22), 
ins(10)9p11.2)[2]/42,sl2,−7,der(13)t(7;13)(q11.2;p11.2)
[2]/45,X,−X[1]
NTPL-313 Caucasian 6 F B-ALL ETV6/RUNX1 fusion 45X,−X,del(6)(q13q21),del(12)(p11.2),del(13)(q31),−18, 
+mar[cp6]/46,XX[14]
NTPL 315 Caucasian 14 M T-ALL Negative 46XY
NTPL-344 Hispanic 3 M B-ALL ETV6/RUNX1 fusion, ETV6 
deletion
45XY,?dic(12;18)(p11.2;p11.2)[11]/46.xy[9]
NTPL-367 Hispanic 15 M B-ALL Negative 46XY
NTPL-386 Non-hispanic 2 M AML RUNX1 amplification 47XY,del(13)(q12q14),+21c[12]/47,ldem,l(7)(q10)
[3]/47,XY,+21c[5]
NTPL-454 Caucasian 16 M T-ALL Negative 46XY
NTPL-511 Unknown 14 M AML Negative 47XY,+8[1]/46,XY[29]
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FigUre 1 | nsg-B2m mice engraft faster and at a higher efficiency compared to nOD/sciD mice. Growth curves showing the increase in the percentage of 
human CD45+ cells in mouse peripheral blood in mice injected with RS4;11 (a) or NTPL-24 (c) cells. Kaplan–Meier survival plots showing the survival of NSG-B2m 
or NOD/SCID mice following transplantation with RS4;11 (B) or NTPL-24 (D) cells. (e) Table summarizing the growth and survival curves described above.
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BD Accuri C6 flow cytometer, BD Biosciences, San Jose, CA, 
USA. The percentage of human cells in mouse peripheral blood 
was calculated using this formula – (No. of human CD45+ cells)/
(No. of human CD45+ cells + No. of mouse CD45+ cells) × 100. 
The increase in this percentage over time was plotted and fitted 
to a non-linear regression curve. The time at which the percent-
age of human cells in mouse peripheral blood reached 1% was 
interpolated from this curve using Prism 6, GraphPad Software, 
San Diego, CA, USA.
For immunophenotypic characterization, blood sample from 
a single mouse (100–150 μl) was split (30–50 μl per tube). APC-
conjugated human CD45 antibody was used in combination 
with FITC-tagged human CD10, CD19, and CD3 antibody for 
double staining. For cytoplasmic CD3 staining, blood was incu-
bated with equal volumes of 1% paraformaldehyde for 15 min 
in the dark. Cells were permeabilized with 0.5% saponin for 
15 min and stained with FITC-conjugated anti-CD3 antibody 
for 5 min. At this point, the RBC were lysed. The stained cells 
within the lymphocyte gate were analyzed by flow cytometry as 
described above.
Xenograft studies
Non-obese diabetic/severe combined immunodeficient and 
NSG-B2m mice were obtained from Jackson Laboratories, Bar 
Harbor, ME, USA. Leukemia cells (3–10 × 106) were transplanted 
into NOD/SCID or NSG-B2m mice via tail-vein injections. Mice 
were maintained in the Nemours Life Science Center following 
the guidelines established by the Nemours Institutional Animal 
Care and Use Committee (IACUC). Disease progression was 
monitored by flow cytometry of mouse peripheral blood drawn 
periodically by submandibular bleeds. Mice were sacrificed by 
carbon dioxide asphyxiation using a method consistent with 
the euthanasia guidelines of the American Veterinary Medical 
Association, when they exhibited disease symptoms, such as 
increased leukemic burden, persistent weight loss, or hind limb 
paralysis. Following sacrifice, leukemic cells were harvested from 
the bone marrow and spleen, and enriched by Ficoll gradient 
centrifugation using Ficoll Paque Plus. All studies involving mice 
were approved by the Nemours IACUC.
statistical analysis
GraphPad Prism software was used for comparison between 
two or more growth curves using the Extra sum-of-squares 
F test. Kaplan–Meir survival curves were compared by Log-rank 
(Mantel–Cox) test. A p value of less than 0.01 was considered 
statistically significant.
resUlTs
all cells engraft Faster and at a higher 
efficiency in nsg-B2m cells compared 
to nOD/sciD Mice
We tested the engraftment rate and efficiency of an ALL cell 
line and a primary sample in NSG-B2m and NOD/SCID mice 
FigUre 2 | Primary leukemia samples can be serial passaged in nsg-B2m mice. NSG-B2m mice were injected with NTPL-24 cells. When the percentage 
of CD45+ cells in mouse peripheral blood reached above 85%, mice were euthanized. Representative flow cytometry plots showing the percentage of human 
leukemic cells in mouse peripheral blood (a), bone marrow (B), and spleen (c) in these mice. (D) Table showing the growth characteristics of leukemia samples 
over multiple passages.
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without the use of sublethal irradiation. Following intravenous 
injection of 3 ×  106 RS4;11 cells, the mice were monitored for 
disease progression by periodic bleeds. The percentage of human 
leukemic cells in mouse peripheral blood was determined by 
flow cytometry using species-specific antibodies. We observed 
that RS4;11 cells engrafted significantly faster in NSG-B2m mice 
as compared to NOD/SCID mice (Figure 1A, p < 0.0001). The 
estimated time taken to attain an average of 1% human CD45+ 
cells in mouse peripheral blood was 11.9 days in NSG-B2m mice 
compared to 20.5  days in NOD/SCID mice (Figure  1E). The 
engraftment efficiency was 100% in NSG-B2m mice, whereas it 
was 88.9% in NOD/SCID mice. Corresponding to the enhanced 
rate of engraftment, the RS4;11-injected NSG-B2m mice suc-
cumbed to disease significantly sooner than NOD/SCID mice 
(Figure 1B, p < 0.0001).
We also compared the engraftment rate and survival of 
NOD/SCID and NSG-B2m mice injected with 10 × 106 cells of 
a primary T-ALL sample, NTPL-24. NSG-B2m mice engrafted 
significantly faster (Figure 1C, p < 0.0001), and their median 
survival was significantly lower (Figure  1D, p <  0.01). The 
rate of engraftment of NTPL-24 in NOD/SCID mice was also 
lower than in NSG-B2m mice (Figure 1E). Interestingly, the 
doubling time of both samples was similar in NSG-B2m 
and NOD/SCID mice suggesting that the initial lag in the 
engraftment precipitated into delayed engraftment. Taken 
together, these data indicate that NSG-B2m mice represent 
a better model for leukemia cell engraftment compared to 
NOD/SCID mice.
The mice were euthanized when they exhibited morbidity 
symptoms. At this point, the percentage of human cells in mouse 
peripheral blood ranged from 60 to 85% depending on the 
leukemia sample injected. A representative flow cytometry plot 
with 87.5% leukemic cells in blood from a mouse injected with 
NTPL-24 cells is shown (Figure 2A). The percentage of engraft-
ment in bone marrow and spleen approached 100% in the case 
of majority of leukemia samples (Figures 2B,C show representa-
tive plots from NTPL-24 xenografts), indicating near complete 
replacement of the murine hematopoietic system with leukemic 
cells. Leukemic cells harvested from the spleens of euthanized 
mice were enriched by Ficoll density gradient centrifugation and 
utilized for injection of new cohorts of mice for secondary and 
tertiary passages. The engraftment characteristics were similar 
across the three passages of NTPL-24 cells (Figure 2D). Doubling 
times for other primary samples were also consistent over serial 
passages in NSG-B2m mice. Data for three representative samples 
are provided (Figure 2D).
nsg-B2m Model system is suitable 
for Drug Testing
RS4;11 cells are sensitive to dexamethasone in vitro and in vivo 
(24, 25). RS4;11 cells (3 × 106) were transplanted in NOD/SCID 
and NSG-B2m mice, as described above. Once the median 
percentage of CD45+ human cells in peripheral blood reached 
1%, mice were dosed with dexamethasone (15 mg/kg M-F), as 
described previously (6). Because of their differential growth lag 
until human cells were detected in mouse blood as described 
above, treatment was started at 4  weeks for NOD/SCID mice 
and at 3  weeks for NSG-B2m mice. Dexamethasone treat-
ment significantly increased the doubling time of RS4;11 cells 
(Figure 3A, p < 0.0001 for each model) and conferred a 4.5-day 
advantage in median survival in both NOD/SCID and NSG-B2m 
mice (Figure 3B, p < 0.005 for NSG-B2m and p < 0.01 for NOD/
SCID). However, the survival range for dexamethasone-treated 
FigUre 4 | engraftment characteristics of all and aMl cell lines in non-irradiated nsg-B2m mice. NSG-B2m mice were injected with ALL cell lines 
(REH, RS4;11, Nalm6) or AML cell lines (HL-60, AML-193, MV4;11). Growth curves show the rise in percentage of human CD45+ cells in peripheral blood in ALL 
(a) and AML (c) cell lines. Kaplan–Meier survival plots showing the survival of NSG-B2m mice following transplantation with ALL (B) or AML (D) cell lines. (e) Table 
summarizing the growth and survival curves in (a,c). (F) Table recaptures the growth and survival curves in (B,D).
FigUre 3 | nsg-B2m model system is suitable for drug testing. NOD/SCID or NSG-B2m mice were injected with RS4;11 cells. When the median percentage 
of CD45+ cells in mouse peripheral blood reached above 1%, mice were randomized into two groups and treated with either vehicle or 15 mg/kg dexamethasone 
(M-F). (a) Growth curves showing the rise in percentage of human CD45+ cells. (B) Kaplan–Meier survival plots showing the survival of NSG-B2m or NOD/SCID 
mice following transplantation with RS4;11.
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NOD/SCID mice was greater than the range of the treated 
NSG-B2m mice. Further studies are needed to determine if 
the survival benefit conferred by dexamethasone treatment is 
comparable between the two models. Nevertheless, these data 
indicated that NSG-B2m model is useful for testing the efficacy 
of therapeutics.
FigUre 5 | engraftment characteristics of primary all and aMl samples in non-irradiated nsg-B2m mice. NSG-B2m mice were injected with primary 
ALL samples (NTPL-20, NTPL-87, NTPL-90, NTPL-92) or primary AML samples (NTPL-60, NTPL-104, NTPL-386). Growth curves show the rise in percentage of 
human CD45+ cells in peripheral blood in primary ALL (a) and AML (c) samples. Kaplan–Meier survival plots showing the survival of NSG-B2m mice following 
transplantation with primary ALL (B) or AML (D) samples. (e) Table summarizing the growth and survival curves in (a,c). (F) Table recaptures the growth and 
survival curves in (B,D).
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evaluation of engraftment rate of all  
and aMl cell lines and Patient samples 
in nsg-B2m Mice
After establishing NSG-B2m as a better model compared to 
NOD/SCID mice using a cell line and a patient sample, we 
subsequently used NSG-B2m mice to determine the engraft-
ment efficiency and kinetics of a variety of cell lines and 
primary samples in an effort to generate xenograft models for 
preclinical evaluation of novel drugs. 5 × 106 cells were injected 
for each sample. The pediatric ALL cell line REH engrafted 
at a 100% efficiency, with engraftment rate (p  >  0.01) and 
median survival (p > 0.01) similar to RS4;11 (Figures 4A,B). 
Nalm6 cells engrafted much faster than REH and RS4;11 and 
showed a significantly shorter median survival of 21  days 
(Figure  4F, p  <  0.0001). Consistent with the reported dif-
ficulties in engraftment of AML cells compared to ALL cells, 
we observed longer lag phases for the three AML cell lines 
HL-60, AML-193, and MV4;11 tested compared to ALL cell 
lines (Figure  4E, p <  0.0001). HL-60 engrafted most rapidly 
among the three AML cell lines (Figure  4C, p  <  0.0001). 
However, the median survival of HL-60 and MV4;11 cells was 
similar (Figure 4D, p = 0.1299), while the median survival of 
AML-193 was significantly different than the other two AML 
cell lines (Figure 4D, p < 0.0001).
Encouraged by the 100% engraftment efficiency observed in 
ALL and AML cell lines, we tested the efficiency of engraftment of 
primary leukemia cells from the bone marrow aspirates obtained 
from pediatric patients under IRB approved protocol. Data for 
engraftment of four ALL and three AML patient samples are 
shown in Figure 5. Similar to the cell lines, we observed a delay 
in the engraftment of 2/3 AML primary samples compared to 
ALL primary samples (Figures 5A,C, p < 0.0001). Surprisingly, 
NTPL-386, a primary AML sample, engrafted rapidly with 
rates similar to primary ALL samples, NTPL-90 and NTPL-92 
(Figures 5B,D). In agreement with the faster engraftment rate, 
NTPL-386 transplanted mice also died sooner, with a median 
survival of only 73 days (Figures 5D,F).
Determination of immunophenotype 
of engrafted samples
To rule out the possibility that the CD45+ human cells arose 
from engraftment of non-malignant cells in primary samples, 
FigUre 6 | immunophenotype confirmation of engrafted primary all and aMl samples. Representative flow cytometry plots from peripheral blood 
of NSG-B2m mice injected with primary leukemia samples (NTPL-20, NTPL-24, NTPL-386) stained with the indicated fluorophore-conjugated antibodies (see 
axis labels). NTPL-20 showed immunoreactivity for CD45 (a), CD10 (B), and CD19 (c), as expected for a precursor B-ALL sample. NTPL-24 (T-ALL) 
without or with fixation and permeabilization showed the absence of surface CD3 (e) but positivity for intracellular CD3 (F), respectively. AML sample 
NTPL-386 was positive for CD45 (g) and CD33 (h) but lacked CD10 immunoreactivity (i). (a–g) were double stained for the indicated antibodies, where as 
(h,i) were single stained with a single antibody indicated on the X-axis. FL-4 on the Y-axis indicates that fluorescent laser 4 was used to generate the 
scatter plots in (h,i).
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we performed immunophenotype determination and char-
acterization of each primary sample. Flow cytometry data on 
representative samples isolated from the peripheral blood of 
transplanted mice are presented here (Figure 6). For each sample, 
we readily distinguished between mouse and human CD45+ cells 
using species-specific antibodies with minimal cross-reactivity 
(Figures 6A,D,G). Antigens CD10 and CD19 are co-expressed 
by the earliest B-cell progenitors and are detected on majority of 
B-precursor ALL cells (26). NTPL-20 B-precursor ALL xenograft 
cells showed CD10 and CD19 positivity, which matched with the 
diagnostic flow cytometry data on patient sample (Figures 6B,C). 
CD3 T-cell receptor antigen is detected in the cytoplasm of 
prothymocytes and precursor T-cells and is found on the cell 
surface of mature T-cells. NTPL-24 precursor T-ALL sample was 
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negative for surface CD3 (Figure 6E) but exhibited cytoplasmic 
CD3 positivity following fixation and permeabilization of blood 
(Figure  6F). CD33 antigen is expressed by 85–90% of AML 
cases and is even used as a target for antibody-based therapies 
(27). NTPL-386 AML sample was positive for surface CD33 
(Figure 6H) but negative for surface CD10 (Figure 6I) in agree-
ment with the flow cytometry profile of patient sample collected 
at diagnosis. Taken together, these data indicate that the primary 
leukemic cells engrafted in NSG-B2m mice are neoplastic and 
faithfully mimic the immunophenotype of the diagnostic patient 
sample.
DiscUssiOn
The identification of the SCID mutation in the Prkdc gene 
in mice that severely impaired lymphopoiesis (28) prompted 
the use of SCID mice to engraft B-precursor ALL cells (29). 
Later studies showed that mice with SCID mutation on NOD 
background (NOD/SCID) had reduced SCID leakiness and 
defects in innate and adaptive immunologic functions (16). 
NOD/SCID mice showed improved engraftment efficiency of 
ALL and AML cells (30, 31). These models were improved (i) by 
utilizing transgenic mice deficient in key genes of the adaptive 
and innate immunity (18, 19, 21, 32), (ii) by host preconditioning 
with sublethal irradiation or treatment with antibodies against 
natural killer cells (33), (iii) by treating mice with human 
cytokines or growth factors (34), or (iv) by generating trans-
genic mice expressing human growth factors (35). Thus, these 
improved models created mice that are practically incapable of 
rejecting human xenografts. We are the first group to utilize 
non-irradiated NSG-B2m mice for engraftment of pediatric 
acute leukemia cells.
Since our objective was to generate cell line-derived or 
patient-derived leukemia xenograft models for preclinical 
drug testing, we chose to compare the engraftment efficiency 
between NSG-B2m mice and NOD/SCID mice that are the 
preferred model for preclinical testing of drugs for pediatric 
leukemia (15). Several groups have reported 70–90% engraft-
ment efficiency for primary pediatric leukemia samples in 
non-irradiated NSG mice (19, 36–38), whereas we achieved 
100% engraftment in NSG-B2m. That NSG mice were the most 
efficient disease model compared to NOD/SCID or NS-B2m 
was demonstrated by direct comparison of the engraftment 
efficiency (19). Engraftment of HL-60 cells in NOD/SCID mice 
was 86% (19). In our hands, NSG-B2m mice showed 100% 
engraftment efficiency for HL-60 cells, indicating an advantage 
of the non-irradiated NSG-B2m mouse model over NSG model 
for studying acute leukemia. Improved engraftment efficiency 
for xenografts was observed in NSGS mice, which are NSG mice 
with constitutive expression of three human cytokines  –  SCF, 
GM-CSF, and IL-3 (35). Future studies with direct comparison 
between NSG, NSGS, and NSG-B2m mice are required to 
determine whether NSG-B2m mice engraft better than NSG 
or NSGS mice.
The severity of the disease was reflected in the engraftment 
potential of the mice. High-risk and relapsed leukemias tend 
to engraft very well in mice; however, good prognosis ALL 
typically took longer or did not engraft at all (30). Primary 
ALL cells isolated from patients with early relapse showed rapid 
engraftment and development of leukemia (39) associated with 
reduced apoptosis signaling (40). The higher engraftment rate 
of poor-outcome ALL samples could be because of the very 
high frequency of leukemia stem cells in these samples (20). 
Similarly, AML engraftment in immunodeficient mice reflected 
the patient outcome i.e., AML samples that engrafted had a 
poorer prognosis (41, 42). Using NSG-B2m mice, we were able 
to engraft primary leukemia samples with variable risk. We also 
observed that high-risk samples, such as NTPL-20 and NTPL-87, 
engrafted faster than samples like NTPL-90 with intermediate 
risk (Figures 5A,E).
The growth rate (or doubling time) in mice has been shown to 
be dependent on the specific leukemia sample (5). In our study, 
the doubling time of RS4;11 cells in NOD/SCID and NSG-B2m 
mice was similar (Figure  1E). NTPL-24 cells also grew at a 
similar growth rate in NOD/SCID or NSG-B2m mice after the 
initial lag phase, which was variable. On the other hand, two 
primary leukemia samples with similar lag phase showed varying 
growth rate in NSG-B2m mice (Figures 5A,E, compare NTPL-90 
and NTPL-92), confirming that the growth rate is an inherent 
characteristic of the leukemia sample and does not depend on 
the model used.
Furthermore, the ability to amplify primary patient samples 
by serial passage is crucial to generate xenograft models for 
preclinical drug testing. We have utilized this model for test-
ing the efficacy of epigenetic drug combination (43), and for 
deciphering the role of annexin II/p11 in homing and engraft-
ment to the bone marrow (32). In conclusion, non-irradiated 
NSG-B2m mouse model faithfully replicates the disease and 
is an efficient model system for engraftment of primary acute 
leukemia samples, for studying the disease biology, and for the 
preclinical drug testing.
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